In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical company known for its innovative work in developing oral integrin therapies. The acquisition, valued at $57 per share in cash, totals approximately $3.2 billion. This acquisition represents a significant premium […]
In a significant move, CBC Group, Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its portfolio company, Hasten Biopharmaceutical, has successfully acquired the asset rights of 14 branded products from South Korean biopharmaceutical company, Celltrion. The deal price remains undisclosed. According to the agreement, Hasten Biopharmaceutical will hold the Marketing Authorization Holder […]
